Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 35,750 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 35,750 shares of the company’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the completion of the transaction, the chief financial officer owned 119,216 shares of the company’s stock, valued at $22,424,529.60. This trade represents a 23.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jack Anders also recently made the following trade(s):

• On Wednesday, September 16th, Jack Anders sold 4,053 shares of Revolution Medicines stock. The shares were sold at an average price of $199.24, for a total value of $807,519.72.

Revolution Medicines Price Performance

NASDAQ RVMD traded down $4.06 during trading hours on Friday, reaching $172.29. 2,654,066 shares of the stock traded hands, compared to its average volume of 2,385,159. The stock has a 50 day simple moving average of $194.46 and a two-hundred day simple moving average of $159.42. Revolution Medicines, Inc. has a 1 year low of $63.50 and a 1 year high of $224.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34. The company has a market cap of $37.26 billion, a price-to-earnings ratio of -18.91 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to the consensus estimate of $25.58 million. During the same period last year, the firm earned ($1.61) EPS. On average, analysts predict that Revolution Medicines, Inc. will post -7.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RVMD. Burkett Financial Services LLC bought a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines during the 2nd quarter valued at about $32,000. Johnson Financial Group Inc. purchased a new stake in Revolution Medicines during the 2nd quarter valued at about $37,000. Silvant Capital Management LLC purchased a new stake in Revolution Medicines during the 2nd quarter valued at about $41,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Revolution Medicines during the 2nd quarter worth approximately $41,000. 94.34% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RVMD shares. HC Wainwright boosted their target price on Revolution Medicines from $280.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Piper Sandler increased their price target on shares of Revolution Medicines from $210.00 to $222.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $275.00 price target on shares of Revolution Medicines in a research report on Thursday, October 15th. William Blair assumed coverage on shares of Revolution Medicines in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Sanford C. Bernstein boosted their price objective on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $262.75.

About Revolution Medicines

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.